Medical Device News Magazine

Monday, May 23, 2022

Ph: 561.316.3330

Home

Press Releases

About

Editorial

Advertise

Health/Lifestyle

Articles

Contact

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

Market Reports

FDA

Executives

Funding

Acquisitions

Non Profits

Hospitals

Subscribe

Biotechnology News Magazine

Dr. Yehia Hashad New EVP of R & D & CMO at Bausch + Lomb Corporation

Dr. Yehia Hashad will join Bausch + Lomb Corporation (“Bausch + Lomb”) as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022.

Dr. Yehia Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11 years he held various roles, including leading Allergan’s global clinical development program for its eye care portfolio. Prior to that, he was with Novartis Pharma AG for five years, where he focused on ophthalmology, and also with T3A Pharma Group for nearly 10 years.

“I am excited that Dr. Hashad will lead the R&D organization and serve as CMO at Bausch + Lomb. He brings more than 25 years of experience working in leading multinational pharmaceutical companies, including expertise in the vision care field, particularly ophthalmic pharmaceuticals,” said Joseph C. Papa, chairman and CEO of Bausch Health. “Dr. Hashad will play a critical role in helping to shape the future of R&D at Bausch + Lomb.”

“I am honored to join Bausch + Lomb, a fully integrated eye health company with nearly 170 years of history, and I look forward to working with Bausch + Lomb’s very talented team of scientists, physicians and engineers to bring forward the next generation of innovative eye health products and services,” said Dr. Hashad.

About Yehia Hashad, M.D.
Effective Jan. 31, 2022, Dr. Hashad will join Bausch + Lomb. Most recently, Dr. Hashad was with Allergan/AbbVie where he served as senior vice president and head of R&D for Allergan Aesthetics from 2020 through August 2021. There, he oversaw the development of more than 40 programs that spanned pharmaceutical products, fillers, reconstructive surgery, devices and consumer skin care. From 2010 until Allergan’s acquisition by AbbVie in 2020, Dr. Hashad held a number of executive R&D positions at Allergan, including senior vice president and head of Global Clinical Development; vice president and global head of Clinical Development, Ophthalmology, Dermatology and Medical Aesthetics; and vice president and global head of the Ophthalmology and Retina therapeutic areas.

Prior to Allergan, Dr. Hashad spent five years with Novartis Pharma AG, where he served as a global medical director for age-related macular degeneration-related treatments Visudyne® and Lucentis® and as a medical director, Ophthalmology, for the European region. From 1996 to 2005, he held positions of increasing responsibility at T3A Pharma Group.

Dr. Hashad obtained his M.S.c. in Medical and Surgical Ophthalmology from Cairo University and a business degree from INSEAD in France. He previously served on the boards of The Glaucoma Research Foundation and the National Alliance of Eye and Vision Research and is currently a board adviser for the University of California Irvine Research Center.

By using this website you agree to accept Medical Device News Magazine Privacy Policy